Administration of Murine Stromal Vascular Fraction Ameliorates Chronic Experimental Autoimmune Encephalomyelitis. (27th August 2013)

• Record Type: Journal Article
• Authors: Semon, Julie A.; Zhang, Xiujuan; Pandey, Amitabh C.; Alandete, Sandra M.; Maness, Catherine; Zhang, Shijia; Scruggs, Brittni A.; Strong, Amy L.; Sharkey, Steven A.; Beuttler, Marc M.; Gimble, Jeffrey M.; Bunnell, Bruce A.
• Is Part Of: Stem cells translational medicine. Volume 2:Number 10(2013)
• Page Start: 789
• Page End: 796
• Publication Date: 2013-08-27
• Subjects: Adipose -- Adult stem cells -- Tissue-specific stem cells -- Stem cells -- Neuroimmune; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.5966/sctm.2013-0032
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract : Murine stromal vascular fraction (SVF) cells were compared with culture‐expanded adipose‐derived stem cells (ASCs) for the treatment of experimental autoimmune encephalitis (EAE) in mice. It was found that SVF cells effectively inhibited EAE disease progression more than culture‐expanded ASCs did, suggesting that they might represent a valuable tool for stem cell‐based therapy in chronic inflammatory disease of the central nervous system. Abstract : Administration of adipose‐derived stromal/stem cells (ASCs) represents a promising therapeutic approach for autoimmune diseases since they have been shown to have immunomodulatory properties. The uncultured, nonexpanded counterpart of ASCs, the stromal vascular fraction (SVF), is composed of a heterogeneous mixture of cells. Although administration of ex vivo culture‐expanded ASCs has been used to study immunomodulatory mechanisms in multiple models of autoimmune diseases, less is known about SVF‐based therapy. The ability of murine SVF cells to treat myelin oligodendrocyte glycoprotein35–55 ‐induced experimental autoimmune encephalitis (EAE) was compared with that of culture‐expanded ASCs in C57Bl/6J mice. A total of 1 × 10 6 SVF cells or ASCs were administered intraperitoneally concomitantly with the induction of disease. The data indicate that intraperitoneal administration of ASCs significantly ameliorated the severity of disease course. They also demonstrate, for the first time, that the SVF effectively inhibited disease severity and was statistically more effective than ASCs. Both cell therapies also demonstrated a reduction in tissue damage, a decrease in inflammatory infiltrates, and a reduction in sera levels of interferon‐γ and interleukin‐12. Based on these data, SVF cells effectively inhibited EAE disease progression more than culture‐expanded ASCs.